MRD-positive B-cell Precursor ALL
The safety of BLINCYTO in patients with MRD-positive B-cell precursor ALL was evaluated in two single-arm clinical studies in which 137 adult patients were treated with BLINCYTO. The median age of the study population was 45 years (range: 18 to 77 years).
The most common adverse reactions (≥ 20%) were pyrexia, infusion-related reactions, headache, infections (pathogen unspecified), tremor, and chills. Serious adverse reactions were reported in 61% of patients. The most common serious adverse reactions (≥ 2%) included pyrexia, tremor, encephalopathy, aphasia, lymphopenia, neutropenia, overdose, device related infection, seizure, and staphylococcal infection. Adverse reactions of Grade 3 or higher were reported in 64% of patients. Discontinuation of therapy due to adverse reactions occurred in 17% of patients; neurologic events were the most frequently reported reasons for discontinuation. There were 2 fatal adverse reactions that occurred within 30 days of the end of BLINCYTO treatment (atypical pneumonia and subdural hemorrhage).
Table 6 summarizes the adverse reactions occurring at a ≥ 10% incidence for any grade or ≥ 5% incidence for Grade 3 or higher.
Table 6. Adverse Reactions Occurring at ≥ 10% Incidence for Any Grade or ≥ 5% Incidence for Grade 3 or Higher in BLINCYTO-treated Adult Patients with MRD-Positive B-cell Precursor ALL| Adverse Reaction | BLINCYTO (N = 137) |
|---|
| Any Grade Grading based on NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. n (%) | Grade ≥ 3 n (%) |
|---|
| Blood and lymphatic system disorders | | |
| Neutropenia Neutropenia includes febrile neutropenia, neutropenia, and neutrophil count decreased. | 21 (15) | 21 (15) |
| Leukopenia Leukopenia includes leukopenia and white blood cell count decreased. | 19 (14) | 13 (9) |
| Thrombocytopenia Thrombocytopenia includes platelet count decreased and thrombocytopenia. | 14 (10) | 8 (6) |
| Cardiac disorders | | |
| Arrhythmia Arrhythmia includes bradycardia, sinus arrhythmia, sinus bradycardia, sinus tachycardia, tachycardia and ventricular extrasystoles. | 17 (12) | 3 (2) |
| General disorders and administration site conditions | | |
| Pyrexia Pyrexia includes body temperature increased and pyrexia. | 125 (91) | 9 (7) |
| Chills | 39 (28) | 0 (0) |
| Infections and infestations | | |
| Infections - pathogen unspecified | 53 (39) | 11 (8) |
| Injury, poisoning and procedural complications | | |
| Infusion-related reaction Infusion-related reaction is a composite term that includes the term infusion-related reaction and the following events occurring with the first 48 hours of infusion and the event lasted ≤ 2 days: cytokine release syndrome, eye swelling, hypertension, hypotension, myalgia, periorbital edema, pruritus generalized, pyrexia, and rash. | 105 (77) | 7 (5) |
| Investigations | | |
| Decreased immunoglobulins Decreased immunoglobulins includes blood immunoglobulin A decreased, blood immunoglobulin G decreased, blood immunoglobulin M decreased, hypogammaglobulinemia, hypoglobulinemia, and immunoglobulins decreased. | 25 (18) | 7 (5) |
| Weight increased | 14 (10) | 1 (< 1) |
| Hypertransaminasemia Hypertransaminasemia includes alanine aminotransferase increased, aspartate aminotransferase increased, and hepatic enzyme increased. | 13 (9) | 9 (7) |
| Musculoskeletal and connective tissue disorders | | |
| Back pain | 16 (12) | 1 (< 1) |
| Nervous system disorders | | |
| Headache May represent ICANS. | 54 (39) | 5 (4) |
| Tremor, Tremor includes essential tremor, intention tremor, and tremor. | 43 (31) | 6 (4) |
| Aphasia | 16 (12) | 1 (< 1) |
| Dizziness | 14 (10) | 1 (< 1) |
| Encephalopathy, Encephalopathy includes cognitive disorder, depressed level of consciousness, disturbance in attention, encephalopathy, lethargy, leukoencephalopathy, memory impairment, somnolence, and toxic encephalopathy. | 14 (10) | 6 (4) |
| Psychiatric disorders | | |
| Insomnia, Insomnia includes initial insomnia, insomnia, and terminal insomnia. | 24 (18) | 1 (< 1) |
| Respiratory, thoracic and mediastinal disorders | | |
| Cough | 18 (13) | 0 (0) |
| Skin and subcutaneous tissue disorders | | |
| Rash Rash includes dermatitis contact, eczema, erythema, rash, and rash maculopapular. | 22 (16) | 1 (< 1) |
| Vascular disorders | | |
| Hypotension | 19 (14) | 1 (< 1) |
Additional adverse reactions in adult patients with MRD-positive ALL that did not meet the threshold criteria for inclusion in Table 6 were:
Blood and lymphatic system disorders: anemia
General disorders and administration site conditions: edema peripheral, pain, and chest pain (includes chest pain and musculoskeletal chest pain)
Hepatobiliary disorders: blood bilirubin increased
Immune system disorders: hypersensitivity and cytokine release syndrome
Infections and infestations: viral infectious disorders, bacterial infectious disorders, and fungal infectious disorders
Injury, poisoning and procedural complications: medication error and overdose (includes overdose and accidental overdose)
Investigations: blood alkaline phosphatase increased
Musculoskeletal and connective tissue disorders: pain in extremity and bone pain
Nervous system disorders: seizure (includes seizure and generalized tonic-clonic seizure), speech disorder, and hypoesthesia
Psychiatric disorders: confusional state, disorientation, and depression
Respiratory, thoracic and mediastinal disorders: dyspnea and productive cough
Vascular disorders: hypertension (includes blood pressure increased and hypertension) flushing (includes flushing and hot flush), and capillary leak syndrome
Relapsed or Refractory B-cell Precursor ALL
The safety of BLINCYTO was evaluated in a randomized, open-label, active-controlled clinical study (TOWER Study) in which 376 adult patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor ALL were treated with BLINCYTO (n = 267) or standard of care (SOC) chemotherapy (n = 109). The median age of BLINCYTO-treated patients was 37 years (range: 18 to 80 years), 60% were male, 84% were White, 7% Asian, 2% were Black or African American, 2% were American Indian or Alaska Native, and 5% were Multiple/Other.
The most common adverse reactions (≥ 20%) in the BLINCYTO arm were infections (bacterial and pathogen unspecified), pyrexia, headache, infusion-related reactions, anemia, febrile neutropenia, thrombocytopenia, and neutropenia. Serious adverse reactions were reported in 62% of patients. The most common serious adverse reactions (≥ 2%) included febrile neutropenia, pyrexia, sepsis, pneumonia, overdose, septic shock, CRS, bacterial sepsis, device related infection, and bacteremia. Adverse reactions of Grade 3 or higher were reported in 87% of patients. Discontinuation of therapy due to adverse reactions occurred in 12% of patients treated with BLINCYTO; neurologic events and infections were the most frequently reported reasons for discontinuation of treatment due to an adverse reaction. Fatal adverse events occurred in 16% of patients. The majority of the fatal events were infections.
The adverse reactions occurring at a ≥ 10% incidence for any grade or ≥ 5% incidence for Grade 3 or higher in the BLINCYTO-treated patients in first cycle of therapy are summarized in Table 7.
Table 7. Adverse Reactions Occurring at ≥ 10% Incidence for Any Grade or ≥ 5% Incidence for Grade 3 or Higher in BLINCYTO-Treated Patients in First Cycle of Therapy for Adult Patients with Relapsed or Refractory B-cell Precursor ALL (TOWER Study)| Adverse Reaction | BLINCYTO (N = 267) | Standard of Care (SOC) Chemotherapy (N = 109) |
|---|
| Any Grade Grading based on NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. n (%) | Grade ≥ 3 n (%) | Any Grade n (%) | Grade ≥ 3 n (%) |
|---|
| Blood and lymphatic system disorders |
| Neutropenia Neutropenia includes agranulocytosis, febrile neutropenia, neutropenia, and neutrophil count decreased. | 84 (31) | 76 (28) | 67 (61) | 61 (56) |
| Anemia Anemia includes anemia and hemoglobin decreased. | 68 (25) | 52 (19) | 45 (41) | 37 (34) |
| Thrombocytopenia Thrombocytopenia includes platelet count decreased and thrombocytopenia. | 57 (21) | 47 (18) | 42 (39) | 40 (37) |
| Leukopenia Leukopenia includes leukopenia and white blood cell count decreased. | 21 (8) | 18 (7) | 9 (8) | 9 (8) |
| Cardiac disorders |
| Arrhythmia Arrhythmia includes arrhythmia, atrial fibrillation, atrial flutter, bradycardia, sinus bradycardia, sinus tachycardia, supraventricular tachycardia, and tachycardia. | 37 (14) | 5 (2) | 18 (17) | 0 (0) |
| General disorders and administration site conditions |
| Pyrexia | 147 (55) | 15 (6) | 43 (39) | 4 (4) |
| Edema Edema includes face edema, fluid retention, edema, edema peripheral, peripheral swelling, and swelling face. | 48 (18) | 3 (1) | 20 (18) | 1 (1) |
| Immune system disorders |
| Cytokine release syndrome Cytokine release syndrome includes cytokine release syndrome and cytokine storm. | 37 (14) | 8 (3) | 0 (0) | 0 (0) |
| Infections and infestations |
| Infections - pathogen unspecified | 74 (28) | 40 (15) | 50 (46) | 35 (32) |
| Bacterial infectious disorders | 38 (14) | 19 (7) | 35 (32) | 21 (19) |
| Viral infectious disorders | 30 (11) | 4 (1) | 14 (13) | 0 (0) |
| Fungal infectious disorders | 27 (10) | 13 (5) | 15 (14) | 9 (8) |
| Injury, poisoning and procedural complications |
| Infusion-related reaction Infusion-related reaction is a composite term that includes the term infusion-related reaction and the following events occurring with the first 48 hours of infusion and the event lasted ≤ 2 days: pyrexia, cytokine release syndrome, hypotension, myalgia, acute kidney injury, hypertension, and rash erythematous. | 79 (30) | 9 (3) | 9 (8) | 1 (1) |
| Investigations |
| Hypertransaminasemia Hypertransaminasemia includes alanine aminotransferase increased, aspartate aminotransferase increased, hepatic enzyme increased, and transaminases increased. | 40 (15) | 22 (8) | 13 (12) | 7 (6) |
| Nervous system disorders |
| Headache May represent ICANS. | 61 (23) | 1 (< 1) | 30 (28) | 3 (3) |
| Skin and subcutaneous tissue disorders |
| Rash Rash includes erythema, rash, rash erythematous, rash generalized, rash macular, rash maculo-papular, rash pruritic, skin exfoliation, and toxic skin eruption. | 31 (12) | 2 (1) | 21 (19) | 0 (0) |
Selected laboratory abnormalities worsening from baseline Grade 0-2 to treatment-related maximal Grade 3-4 in first cycle of therapy are shown in Table 8.
Table 8. Selected Laboratory Abnormalities Worsening from Baseline Grade 0-2 to Treatment-related Maximal Grade 3-4Includes only patients who had both baseline and at least one laboratory measurement during first cycle of therapy available.
in First Cycle of Therapy for Adult Patients with Relapsed or Refractory B-cell Precursor ALL (TOWER Study) | BLINCYTO Grade 3 or 4 (%) | SOC Chemotherapy Grade 3 or 4 (%) |
|---|
| Hematology | | |
| Decreased lymphocyte count | 80 | 83 |
| Decreased white blood cell count | 53 | 97 |
| Decreased hemoglobin | 29 | 43 |
| Decreased neutrophil count | 57 | 68 |
| Decreased platelet count | 47 | 85 |
| Chemistry | | |
| Increased ALT | 11 | 11 |
| Increased bilirubin | 5 | 4 |
| Increased AST | 8 | 4 |
Other important adverse reactions from pooled relapsed or refractory B-cell precursor ALL studies were:
Blood and lymphatic system disorders: lymphadenopathy, hemophagocytic lymphohistiocytosis, and leukocytosis (includes leukocytosis and white blood cell count increased)
General disorders and administration site conditions: chills, chest pain (includes chest discomfort, chest pain, musculoskeletal chest pain, and non-cardiac chest pain), pain, body temperature increased, hyperthermia, and systemic inflammatory response syndrome
Hepatobiliary disorders: hyperbilirubinemia (includes blood bilirubin increased and hyperbilirubinemia)
Immune system disorders: hypersensitivity (includes hypersensitivity, anaphylactic reaction, angioedema, dermatitis allergic, drug eruption, drug hypersensitivity, erythema multiforme, and urticaria)
Injury, poisoning and procedural complications: medication error and overdose (includes overdose, medication error, and accidental overdose)
Investigations: weight increased, decreased immunoglobulins (includes immunoglobulins decreased, blood immunoglobulin A decreased, blood immunoglobulin G decreased, blood immunoglobulin M decreased, and hypogammaglobulinemia), blood alkaline phosphatase increased, and hypertransaminasemia
Metabolism and nutrition disorders: tumor lysis syndrome
Musculoskeletal and connective tissue disorders: back pain, bone pain, and pain in extremity
Nervous system disorders: tremor (resting tremor, intention tremor, essential tremor, and tremor), altered state of consciousness (includes altered state of consciousness, depressed level of consciousness, disturbance in attention, lethargy, mental status changes, stupor, and somnolence), dizziness, memory impairment, seizure (includes seizure, and atonic seizure), aphasia, cognitive disorder, speech disorder, hypoesthesia, encephalopathy, paresthesia, and cranial nerve disorders (trigeminal neuralgia, trigeminal nerve disorder, sixth nerve paralysis, cranial nerve disorder, facial nerve disorder, and facial paresis)
Psychiatric disorders: insomnia, disorientation, confusional state, and depression (includes depressed mood, depression, suicidal ideation, and completed suicide)
Respiratory, thoracic and mediastinal disorders: dyspnea (includes acute respiratory failure, dyspnea, dyspnea exertional, respiratory failure, respiratory distress, bronchospasm, bronchial hyperreactivity, tachypnea, and wheezing), cough, and productive cough
Vascular disorders: hypotension (includes blood pressure decreased, hypotension, hypovolemic shock, and circulatory collapse), hypertension (includes blood pressure increased, hypertension, and hypertensive crisis), flushing (includes flushing and hot flush), and capillary leak syndrome
B-cell Precursor ALL in the Consolidation Phase
Study E1910
The safety of a consolidation regimen comprised of multiple cycles of BLINCYTO monotherapy in addition to multiple cycles of chemotherapy (BLINCYTO arm) was evaluated in a randomized trial in adult patients with newly diagnosed Philadelphia chromosome-negative B-cell precursor ALL (Study E1910) [NCT02003222] [see Clinical Studies (14.3)] which included 111 patients treated in the BLINCYTO arm and 112 patients treated in the chemotherapy alone arm. In the BLINCYTO arm, the median (range) of cycles was 8 (1-8) (4 cycles of BLINCYTO and 4 cycles of chemotherapy). In the chemotherapy alone arm, the median (range) of cycles was 4 (1-4).
Fatal adverse reactions occurred in 2 patients (2%) during BLINCYTO cycles and were due to infection (n = 1) and coagulopathy (n = 1). Permanent discontinuation of BLINCYTO due to an adverse reaction occurred in 2% of patients. Dosage interruptions of BLINCYTO due to an adverse reaction occurred in 5% of patients. Dose reductions of BLINCYTO due to an adverse reaction occurred in 28% of patients.
The most common (≥ 20%) adverse reactions during consolidation cycles in the BLINCYTO arm were neutropenia, thrombocytopenia, anemia, leukopenia, headache, infection, nausea, lymphopenia, diarrhea, musculoskeletal pain, and tremor. The adverse reactions occurring at a difference between arms in incidence of ≥ 10% for All Grades or ≥ 5% for Grade 3 or higher are summarized in Table 9.
Table 9. Adverse Reactions with a Difference Between Arms of ≥ 10% for Any Grade or ≥ 5% for Grade 3 or 4 during Consolidation (Study E1910) | Consolidation Consisting of |
|---|
| Adverse Reaction | BLINCYTO Cycles + Chemotherapy Cycles (n = 111) | Chemotherapy Cycles Alone (n = 112) |
|---|
All Grades (%)Includes the following fatal adverse reaction: infection (n = 1). | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%) |
|---|
| Blood and lymphatic system disorders |
| Neutropenia Other related adverse reactions included: | 82 | 77 | 89 | 89 |
| Thrombocytopenia | 75 | 57 | 75 | 71 |
| Anemia | 59 | 29 | 50 | 38 |
| Leukopenia | 43 | 41 | 57 | 56 |
| Lymphopenia | 32 | 30 | 25 | 23 |
| Febrile neutropenia | 19 | 19 | 25 | 25 |
| Gastrointestinal disorders |
| Nausea Nausea: vomiting; | 32 | 5 | 22 | 4 |
| Diarrhea | 29 | 3 | 15 | 3 |
| Immune system disorders |
| Cytokine release syndrome Cytokine release syndrome: capillary leak syndrome; | 16 | 4 | 0 | 0 |
| Infections and infestations |
| Infection – pathogen unspecified | 35 | 31 | 22 | 21 |
| Musculoskeletal and connective tissue disorders |
| Musculoskeletal pain Musculoskeletal pain: pain in extremity, back pain, arthralgia, myalgia, neck pain, flank pain, bone pain, non-cardiac chest pain; | 23 | 5 | 5 | 4 |
| Nervous system disorders |
| Headache May represent ICANS. | 41 | 5 | 30 | 5 |
| Tremor | 23 | 3 | 3 | 0 |
| Aphasia Aphasia: dysarthria. , | 10 | 8 | 0 | 0 |
| Vascular disorders | | | | |
| Hypertension | 12 | 10 | 5 | 3 |
Study 20120215
The safety of BLINCYTO as the 3rd cycle of the consolidation phase was evaluated in a randomized, open-label study (Study 20120215) following induction and two cycles of consolidation chemotherapy in pediatric and young adult patients with high-risk first-relapsed B-cell precursor ALL [see Clinical Studies (14.3)]. The study included 54 patients treated with one cycle of BLINCYTO and 52 patients treated with one cycle of chemotherapy.
Serious adverse reactions occurred in 28% of patients who received BLINCYTO. Permanent discontinuation of BLINCYTO due to an adverse reaction occurred in 4% of patients. Adverse reactions that led to discontinuation included nervous system disorder and seizure. Dosage interruptions of BLINCYTO due to an adverse reaction occurred in 11% of patients. Adverse reactions which required dosage interruption in > 2% of patients included nervous system disorder.
The most common (≥ 20%) adverse reactions in the BLINCYTO arm were pyrexia, nausea, headache, rash, hypogammaglobulinemia, and anemia. The adverse reactions occurring at a difference of ≥ 10% incidence for any grade or at a difference of ≥ 5% incidence for Grade 3 or 4 between the BLINCYTO arm and chemotherapy arm are summarized in Table 10.
Table 10. Adverse Reactions with a Difference Between Arms of ≥ 10% for Any Grade or ≥ 5% for Grade 3 or 4 during Consolidation Cycle 3 (Study 20120215)| Adverse Reaction | BLINCYTO (n = 54) | Chemotherapy (n = 52) |
|---|
All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%) |
|---|
| Blood and lymphatic system disorders |
| Anemia Other related adverse reactions included: | 24 | 15 | 46 | 42 |
| Neutropenia | 19 | 17 | 35 | 31 |
| Thrombocytopenia | 15 | 15 | 39 | 35 |
| Febrile neutropenia | 2 | 2 | 25 | 25 |
| Gastrointestinal disorders |
| Nausea Nausea: vomiting; | 43 | 2 | 31 | 2 |
| Abdominal pain | 13 | 0 | 23 | 2 |
| Stomatitis Stomatitis: mouth ulceration, mucosal inflammation; | 11 | 4 | 60 | 29 |
| General disorders and administration site conditions |
| Pyrexia | 76 | 6 | 19 | 0 |
| Hepatobiliary disorders |
| Liver function test abnormal Liver function test abnormal: alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyltransferase increased, hypertransaminasemia; | 9 | 6 | 27 | 17 |
| Immune system disorders |
| Hypogammaglobulinemia | 24 | 2 | 12 | 2 |
| Infections and infestations |
| Infection – pathogen unspecified | 13 | 6 | 29 | 10 |
| Musculoskeletal and connective tissue disorders |
| Musculoskeletal pain Musculoskeletal pain: back pain, pain in extremity, bone pain; | 9 | 0 | 29 | 2 |
| Nervous system disorders | | | | |
| Headache May represent ICANS. | 37 | 0 | 15 | 0 |
| Skin and subcutaneous disorders |
| Rash | 22 | 2 | 12 | 0 |
| Vascular disorders | | | | |
| Hemorrhage Hemorrhage: Epistaxis, petechiae, hemarthrosis, hematoma, hematuria. | 11 | 2 | 23 | 6 |
Risk Summary
Based on its mechanism of action, BLINCYTO may cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. There are no available data on the use of BLINCYTO in pregnant women to evaluate for a drug-associated risk. In animal reproduction studies, a murine surrogate molecule administered to pregnant mice crossed the placental barrier (see Data).
Blinatumomab causes T-cell activation and cytokine release; immune activation may compromise pregnancy maintenance. In addition, based on expression of CD19 on B-cells and the finding of B-cell depletion in non-pregnant animals, blinatumomab can cause B-cell lymphocytopenia in infants exposed to blinatumomab in-utero. Advise pregnant women of the potential risk to a fetus.
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
Clinical Considerations
Fetal/Neonatal Adverse Reactions
Due to the potential for B-cell lymphocytopenia in infants following exposure to BLINCYTO in utero, the infant's B lymphocytes should be monitored before the initiation of live virus vaccination [see Warnings and Precautions (5.11)].
Data
Animal Data
Animal reproduction studies have not been conducted with blinatumomab. In embryo-fetal developmental toxicity studies, a murine surrogate molecule was administered intravenously to pregnant mice during the period of organogenesis. The surrogate molecule crossed the placental barrier and did not cause embryo-fetal toxicity or teratogenicity. The expected depletions of B and T cells were observed in the pregnant mice, but hematological effects were not assessed in fetuses.
Risk Summary
There is no information regarding the presence of blinatumomab in human milk, the effects on the breastfed infant, or the effects on milk production. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in breastfed infants from BLINCYTO, including B-cell lymphocytopenia, advise patients not to breastfeed during treatment with BLINCYTO and for 48 hours after the last dose.
Pregnancy Testing
Verify the pregnancy status of females of reproductive potential prior to initiating BLINCYTO treatment.
Contraception
Females
Advise females of reproductive potential to use effective contraception during treatment with BLINCYTO and for 48 hours after the last dose.
Minimal Residual Disease (MRD)-Positive B-cell Precursor ALL
The safety and efficacy of BLINCYTO for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% have been established in pediatric patients one month and older. Use of BLINCYTO is supported by evidence from two randomized, controlled trials (Study AALL1331, NCT02101853 and Study 20120215, NCT02393859) [see Clinical Studies (14.3)] in pediatric patients with first relapsed B-cell precursor ALL. Both studies included pediatric patients with MRD-positive B-cell precursor ALL. The studies included pediatric patients treated with BLINCYTO in the following age groups: 6 infants (1 month up to less than 2 years), 165 children (2 years up to less than 12 years), and 70 adolescents (12 years to less than 17 years). In general, the adverse reactions in BLINCYTO-treated pediatric patients were similar in type to those seen in adult patients with MRD-positive ALL [see Adverse Reactions (6.1)], and no differences in safety were observed between the different pediatric age subgroups.
Relapsed or Refractory B-cell Precursor ALL
The safety and efficacy of BLINCYTO have been established in pediatric patients one month and older with relapsed or refractory B-cell precursor ALL. Use of BLINCYTO is supported by a single-arm trial in pediatric patients with relapsed or refractory B-cell precursor ALL. This study included pediatric patients in the following age groups: 10 infants (1 month up to less than 2 years), 40 children (2 years up to less than 12 years), and 20 adolescents (12 years to less than 18 years). No differences in efficacy were observed between the different age subgroups [see Clinical Studies (14.2)].
In general, the adverse reactions in BLINCYTO-treated pediatric patients with relapsed or refractory ALL were similar in type to those seen in adult patients with relapsed or refractory B-cell precursor ALL [see Adverse Reactions (6.1)]. Adverse reactions that were observed more frequently (≥ 10% difference) in the pediatric population compared to the adult population were pyrexia (80% vs. 61%), hypertension (26% vs. 8%), anemia (41% vs. 24%), infusion-related reaction (49% vs. 34%), thrombocytopenia (34% vs. 21%), leukopenia (24% vs. 11%), and weight increased (17% vs. 6%).
In pediatric patients less than 2 years old (infants) with relapsed or refractory ALL, the incidence of neurologic toxicities was not significantly different than for the other age groups, but its manifestations were different; the only event terms reported were agitation, headache, insomnia, somnolence, and irritability. Infants also had an increased incidence of hypokalemia (50%) compared to other pediatric age cohorts (15-20%) or adults (17%).
B-cell Precursor ALL in the Consolidation Phase
The safety and efficacy of BLINCYTO for the treatment of Philadelphia-chromosome negative B-cell precursor ALL in the consolidation phase have been established in pediatric patients one month and older. Use of BLINCYTO for this indication is supported by extrapolation from a randomized controlled study in adults (Study E1910, NCT02003222) and evidence from two randomized, controlled studies in pediatric patients (Study 20120215 and Study AALL1331) [see Adverse Reactions (6.1), Use in Specific Populations (8.4), Clinical Pharmacology (12.3), and Clinical Studies (14.3)].
Benzyl Alcohol Toxicity in Neonates
Serious and fatal adverse reactions, including "gasping syndrome," can occur in very low birth weight (VLBW) neonates born weighing less than 1500 g, and early preterm neonates (infants born less than 34 weeks gestational age) treated with benzyl alcohol-preserved drugs intravenously. The "gasping syndrome" is characterized by central nervous system depression, metabolic acidosis, and gasping respirations. In these cases, benzyl alcohol dosages of 99 to 234 mg/kg/day produced high concentrations of benzyl alcohol and its metabolite in the blood and urine (blood concentration of benzyl alcohol were 0.61 to 1.378 mmol/L). Additional adverse reactions included gradual neurological deterioration, seizures, intracranial hemorrhage, hematologic abnormalities, skin breakdown, hepatic and renal failure, hypotension, bradycardia, and cardiovascular collapse. The minimum amount of benzyl alcohol at which serious adverse reactions may occur in neonates is not known [see Warnings and Precautions (5.12)].
Use the preservative-free formulations of BLINCYTO where possible in neonates. When prescribing BLINCYTO (with preservative) in neonatal patients, consider the combined daily metabolic load of benzyl alcohol from all sources including BLINCYTO (with preservative). The BLINCYTO 72-Hour bag (with preservative) and 96-Hour bag (with preservative) contain 2.5 mg of benzyl alcohol per mL, and the 7-Day bag (with preservative) contains 7.4 mg of benzyl alcohol per mL. The administration of BLINCYTO as a 72-hour, 96-hour, and 7-day infusion is not recommended for patients weighing less than 5.4 kg [see Warnings and Precautions (5.12)].
Benzyl alcohol administration may contribute to metabolic acidosis in pediatric patients, particularly those with immaturity of the metabolic pathway for alcohol, or those with underlying conditions or receiving concomitant medications that could predispose to acid base imbalance. Monitor these patients during use of BLINCYTO (with preservative) for new or worsening metabolic acidosis.
Distribution
The estimated mean (SD) volume of distribution based on terminal phase (Vz) was 5.27 (4.37) L with continuous intravenous infusion of blinatumomab.
Elimination
The estimated mean (SD) systemic clearance with continuous intravenous infusion in patients receiving blinatumomab in clinical studies was 3.10 (2.94) L/hour. The mean (SD) half-life was 2.20 (1.34) hours. Negligible amounts of blinatumomab were excreted in the urine at the tested clinical doses.
Metabolism
The metabolic pathway of blinatumomab has not been characterized. Like other protein therapeutics, blinatumomab is expected to be degraded into small peptides and amino acids via catabolic pathways.
Specific Populations
There were no clinically meaningful differences in the pharmacokinetics of blinatumomab based on age (0.6 to 80 years of age), sex, race (72% White, 17% Asian, 3% Black), ethnicity, Philadelphia chromosome status or mild (total bilirubin ≤ upper limit of normal [ULN] and AST > ULN or total bilirubin > 1 to 1.5 × ULN and any AST) or moderate hepatic impairment (total bilirubin > 1.5 to 3 × ULN and any AST). The effect of other races or severe hepatic impairment (total bilirubin > 3 × ULN, any AST) on the pharmacokinetics of blinatumomab is unknown. Body surface area (0.4 to 2.9 m2) influences the pharmacokinetics of blinatumomab, supporting BSA-based dosing in patients < 45 kg.
Pediatric Patients
The pharmacokinetics of blinatumomab appear linear over a dose range from 5 to 30 mcg/m2/day in pediatric patients. At the recommended doses of 5 and 15 mcg/m2/day for the treatment of relapsed or refractory B-cell precursor ALL, the mean (SD) steady-state concentration (Css) values were 162 (179) and 533 (392) pg/mL, respectively. The pharmacokinetics of blinatumomab in pediatric patients with MRD-positive B-cell precursor ALL and in pediatric patients with B-cell precursor ALL in the consolidation phase were similar to pediatric patients with relapsed or refractory ALL.
In all pediatric patients with ALL, the estimated mean (SD) volume of distribution (Vz), clearance (CL), and terminal half-life (t1/2,z) in Cycle 1 were 4.14 (3.32) L/m2, 1.65 (1.62) L/hour/m2, and 2.14 (1.44) hours, respectively.
The steady-state concentrations of blinatumomab were comparable in adult and pediatric patients at the equivalent dose levels based on BSA-based regimens.
Patients with Renal Impairment
Pharmacokinetic analyses showed an approximately 2-fold difference in mean blinatumomab clearance values between patients with moderate renal impairment (CrCL ranging from 30 to 59 mL/min, N = 49) and normal renal function (CrCL more than 90 mL/min, N = 674). However, high interpatient variability was discerned (CV% up to 98.4%), and clearance values in renal impaired patients were essentially within the range observed in patients with normal renal function. There is no information available in patients with severe renal impairment (CrCL 15-29 mL/min) or patients on hemodialysis.
Drug Interaction Studies
Transient elevation of cytokines may suppress CYP450 enzyme activities [see Drug Interactions (7) and Clinical Pharmacology (12.2)].
BLAST Study
The efficacy of BLINCYTO was evaluated in an open-label, multicenter, single-arm study (BLAST Study) [NCT01207388] that included patients who were ≥ 18 years of age, had received at least 3 chemotherapy blocks of standard ALL therapy, were in hematologic complete remission (defined as < 5% blasts in bone marrow, absolute neutrophil count > 1 Gi/L, platelets > 100 Gi/L) and had MRD at a level of ≥ 0.1% using an assay with a minimum sensitivity of 0.01%. BLINCYTO was administered at a constant dose of 15 mcg/m2/day (equivalent to the recommended dosage of 28 mcg/day) intravenously for all treatment cycles. Patients received up to 4 cycles of treatment. Dose adjustment was possible in case of adverse events.
The treated population included 86 patients in first or second hematologic complete remission (CR1 or CR2). The demographics and baseline characteristics are shown in Table 11. The median number of treatment cycles was 2 (range: 1 to 4). Following treatment with BLINCYTO, 45 out of 61 (73.8%) patients in CR1 and 14 out of 25 (56.0%) patients in CR2 underwent allogeneic hematopoietic stem cell transplantation in continuous hematologic complete remission.
Table 11. Demographics and Baseline Characteristics in BLAST Study| Characteristics | BLINCYTO (N = 86) |
|---|
| Age | |
| Median, years (min, max) | 43 (18, 76) |
| ≥ 65 years, n (%) | 10 (12) |
| Males, n (%) | 50 (58) |
| Race, n (%) | |
| Asian | 1 (1) |
| Other (mixed) | 0 (0) |
| White | 76 (88) |
| Unknown | 9 (11) |
| Philadelphia chromosome disease status, n (%) | |
| Positive | 1 (1) |
| Negative | 85 (99) |
| Relapse history, n (%) | |
| Patients in 1st CR | 61 (71) |
| Patients in 2nd CR | 25 (29) |
| MRD level at baseline Assessed centrally using an assay with minimum sensitivity of 0.01%. , n (%) | |
| ≥ 10% | 7 (8) |
| ≥ 1% and < 10% | 34 (40) |
| ≥ 0.1% and < 1% | 45 (52) |
Efficacy was based on achievement of undetectable MRD within one cycle of BLINCYTO treatment and hematological relapse-free survival (RFS). The assay used to assess MRD response had a sensitivity of 0.01% for 6 patients and ≤ 0.005% for 80 patients. Overall, undetectable MRD was achieved by 70 patients (81.4%: 95% CI: 71.6%, 89.0%). The median hematological RFS was 22.3 months. Table 12 shows the MRD response and hematological RFS by remission number.
Table 12. Efficacy Results in Patients ≥ 18 Years of Age with MRD-positive B-cell Precursor ALL (BLAST Study) | Patients in CR1 (n = 61) | Patients in CR2 (n = 25) |
|---|
| Complete MRD response Complete MRD response was defined as the absence of detectable MRD confirmed in an assay with minimum sensitivity of 0.01%. , n (%), [95% CI] | 52 (85.2) [73.8, 93.0] | 18 (72.0) [50.6, 87.9] |
| Median hematological relapse-free survival Relapse was defined as either hematological or extramedullary relapse, secondary leukemia, or death due to any cause; Includes time after transplantation; Kaplan-Meier estimate. in months (range) | 35.2 (0.4, 53.5) | 12.3 (0.7, 42.3) |
Undetectable MRD was achieved by 65 of 80 patients (81.3%: 95% CI: 71.0%, 89.1%) with an assay sensitivity of at least 0.005%. The estimated median hematological RFS among the 80 patients using the higher sensitivity assay was 24.2 months (95% CI: 17.9, NE).
TOWER Study
The efficacy of BLINCYTO was compared to standard of care (SOC) chemotherapy in a randomized, open-label, multicenter study (TOWER Study) [NCT02013167]. Eligible patients were ≥ 18 years of age with relapsed or refractory B-cell precursor ALL [> 5% blasts in the bone marrow and refractory to primary induction therapy or refractory to last therapy, untreated first relapse with first remission duration < 12 months, untreated second or later relapse, or relapse at any time after allogeneic hematopoietic stem cell transplantation (alloHSCT)]. BLINCYTO was administered at 9 mcg/day on Days 1-7 and 28 mcg/day on Days 8-28 for Cycle 1, and 28 mcg/day on Days 1-28 for Cycles 2-5 in 42-day cycles and for Cycles 6-9 in 84-day cycles. Dose adjustment was possible in case of adverse events. SOC chemotherapy included fludarabine, cytarabine arabinoside, and granulocyte colony-stimulating factor (FLAG); high-dose cytarabine arabinoside (HiDAC); high-dose methotrexate- (HDMTX) based combination; or clofarabine/clofarabine-based regimens.
There were 405 patients randomized 2:1 to receive BLINCYTO or investigator-selected SOC chemotherapy. Randomization was stratified by age (< 35 years vs. ≥ 35 years of age), prior salvage therapy (yes vs. no), and prior alloHSCT (yes vs. no) as assessed at the time of consent. The demographics and baseline characteristics were well-balanced between the two arms (see Table 13).
Table 13. Demographics and Baseline Characteristics in TOWER Study| Characteristics | BLINCYTO (N = 271) | Standard of Care (SOC) Chemotherapy (N = 134) |
|---|
| Age |
| Median, years (min, max) | 37 (18, 80) | 37 (18, 78) |
| < 35 years, n (%) | 124 (46) | 60 (45) |
| ≥ 35 years, n (%) | 147 (54) | 74 (55) |
| ≥ 65 years, n (%) | 33 (12) | 15 (11) |
| ≥ 75 years, n (%) | 10 (4) | 2 (2) |
| Males, n (%) | 162 (60) | 77 (58) |
| Race, n (%) |
| American Indian or Alaska Native | 4 (2) | 1 (1) |
| Asian | 19 (7) | 9 (7) |
| Black (or African American) | 5 (2) | 3 (2) |
| Multiple | 2 (1) | 0 |
| Native Hawaiian or Other Pacific Islander | 1 (0) | 1 (1) |
| Other | 12 (4) | 8 (6) |
| White | 228 (84) | 112 (84) |
| Prior salvage therapy | 171 (63) | 70 (52) |
| Prior alloHSCT alloHSCT = allogeneic hematopoietic stem cell transplantation. | 94 (35) | 46 (34) |
| Eastern Cooperative Group Status - n (%) |
| 0 | 96 (35) | 52 (39) |
| 1 | 134 (49) | 61 (46) |
| 2 | 41 (15) | 20 (15) |
| Unknown | 0 | 1 (1) |
| Refractory to salvage treatment - n (%) |
| Yes | 87 (32) | 34 (25) |
| No | 182 (67) | 99 (74) |
| Unknown | 2 (1) | 1 (1) |
| Maximum of central/local bone marrow blasts - n (%) |
| ≤ 5% | 0 | 0 |
| > 5 to < 10% | 9 (3) | 7 (5) |
| 10 to < 50% | 60 (22) | 23 (17) |
| ≥ 50% | 201 (74) | 104 (78) |
| Unknown | 1 (0) | 0 |
Of the 271 patients randomized to the BLINCYTO arm, 267 patients received BLINCYTO treatment. The median number of treatment cycles was two (range: 1 to 9 cycles); 267 (99%) received Cycles 1-2 (induction), 86 (32%) received Cycles 3-5 (consolidation), and 27 (10%) received Cycles 6-9 (continued therapy). Of the 134 patients on the SOC arm, 25 dropped out prior to start of study treatment, and 109 patients received a median of 1 treatment cycle (range: 1 to 4 cycles).
The determination of efficacy was based on overall survival (OS). The study demonstrated statistically significant improvement in OS for patients treated with BLINCYTO as compared to SOC chemotherapy.
See Figure 1 and Table 14 below for efficacy results from the TOWER Study.
| Figure 1. Kaplan-Meier Curve of Overall Survival in TOWER Study |
|
Table 14. Efficacy Results in Patients ≥ 18 Years of Age with Philadelphia Chromosome-Negative Relapsed or Refractory B-cell Precursor ALL (TOWER Study) | BLINCYTO (N = 271) | SOC Chemotherapy (N = 134) |
|---|
| Overall Survival |
| Number of deaths (%) | 164 (61) | 87 (65) |
| Median, months [95% CI] | 7.7 [5.6, 9.6] | 4.0 [2.9, 5.3] |
| Hazard Ratio [95% CI] Based on stratified Cox's model. | 0.71 [0.55, 0.93] |
| p-value The p-value was derived using stratified log rank test. | 0.012 |
| Overall Response |
| CR CR (complete remission) was defined as ≤ 5% blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts (platelets > 100,000/microliter and absolute neutrophil counts [ANC] > 1,000/microliter). /CRh*CRh* (complete remission with partial hematologic recovery) was defined as ≤ 5% blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts (platelets > 50,000/microliter and ANC > 500/microliter). , n (%) [95% CI] | 115 (42) [37, 49] | 27 (20) [14, 28] |
| Treatment difference [95% CI] | 22 [13, 31] |
| p-value The p-value was derived using Cochran-Mantel-Haenszel test. | < 0.001 |
| CR, n (%) [95% CI] | 91 (34) [28, 40] | 21 (16) [10, 23] |
| Treatment difference [95% CI] | 18 [10, 26] |
| p-value | < 0.001 |
| MRD Response MRD (minimum residual disease) response was defined as MRD by PCR or flow cytometry < 1 × 10-4 (0.01%). for CR/CRh* |
| n1/n2 (%) n1: number of patients who achieved MRD response and CR/CRh*; n2: number of patients who achieved CR/CRh* and had a postbaseline assessment. [95% CI] | 73/115 (64) [54, 72] | 14/27 (52) [32, 71] |
Study MT103-211
Study MT103-211 [NCT01466179] was an open-label, multicenter, single-arm study. Eligible patients were ≥ 18 years of age with Philadelphia chromosome-negative relapsed or refractory B-cell precursor ALL (relapsed with first remission duration of ≤ 12 months in first salvage or relapsed or refractory after first salvage therapy or relapsed within 12 months of alloHSCT, and had ≥ 10% blasts in bone marrow).
BLINCYTO was administered as a continuous intravenous infusion. The recommended dose for this study was determined to be 9 mcg/day on Days 1-7 and 28 mcg/day on Days 8-28 for Cycle 1, and 28 mcg/day on Days 1-28 for subsequent cycles. Dose adjustment was possible in case of adverse events. The treated population included 185 patients who received at least 1 infusion of BLINCYTO; the median number of treatment cycles was 2 (range: 1 to 5). Patients who responded to BLINCYTO but later relapsed had the option to be retreated with BLINCYTO. Among treated patients, the median age was 39 years (range: 18 to 79 years), 63 out of 185 (34.1%) had undergone HSCT prior to receiving BLINCYTO, and 32 out of 185 (17.3%) had received more than 2 prior salvage therapies.
Efficacy was based on the complete remission (CR) rate, duration of CR, and proportion of patients with an MRD-negative CR/CR with partial hematological recovery (CR/CRh*) within 2 cycles of treatment with BLINCYTO. Table 15 shows the efficacy results from this study. The HSCT rate among those who achieved CR/CRh* was 39% (30 out of 77).
Table 15. Efficacy Results in Patients ≥ 18 Years of Age with Philadelphia Chromosome-Negative Relapsed or Refractory B-cell Precursor ALL (Study MT103-211) | N = 185 |
|---|
| CR CR (complete remission) was defined as ≤ 5% of blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts (platelets > 100,000/microliter and absolute neutrophil counts [ANC] > 1,000/microliter). | CRh* CRh* (complete remission with partial hematological recovery) was defined as ≤ 5% of blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts (platelets > 50,000/microliter and ANC > 500/microliter). | CR/CRh* |
|---|
n (%) [95% CI] | 60 (32.4) [25.7, 39.7] | 17 (9.2) [5.4, 14.3] | 77 (41.6) [34.4, 49.1] |
| MRD response MRD (minimal residual disease) response was defined as MRD by PCR < 1 × 10-4 (0.01%). |
| n1/n2 (%) n1: number of patients who achieved MRD response and the respective remission status; n2: number of patients who achieved the respective remission status. Six CR/CRh* responders with missing MRD data were considered as MRD-nonresponders. [95% CI] | 48/60 (80.0) [67.7, 89.2] | 10/17 (58.8) [32.9, 81.6] | 58/77 (75.3) [64.2, 84.4] |
| DOR/RFS DOR (duration of response)/RFS (relapse-free survival) was defined as time since first response of CR or CRh* to relapse or death, whichever is earlier. Relapse was defined as hematological relapse (blasts in bone marrow greater than 5% following CR) or an extramedullary relapse. |
| Median (months) (range) | 6.7 (0.46 – 16.5) | 5.0 (0.13 – 8.8) | 5.9 (0.13 – 16.5) |
ALCANTARA Study
The efficacy of BLINCYTO for treatment of Philadelphia chromosome-positive B-cell precursor ALL was evaluated in an open-label, multicenter, single-arm study (ALCANTARA Study) [NCT02000427]. Eligible patients were ≥ 18 years of age with Philadelphia chromosome-positive B-cell precursor ALL, relapsed or refractory to at least 1 second generation or later tyrosine kinase inhibitor (TKI), or intolerant to second generation TKI, and intolerant or refractory to imatinib mesylate.
BLINCYTO was administered at 9 mcg/day on Days 1-7 and 28 mcg/day on Days 8-28 for Cycle 1, and 28 mcg/day on Days 1-28 for subsequent cycles. Dose adjustment was possible in case of adverse events.
The treated population included 45 patients who received at least one infusion of BLINCYTO; the median number of treatment cycles was 2 (range: 1 to 5). The demographics and baseline characteristics are shown in Table 16.
Table 16. Demographics and Baseline Characteristics in ALCANTARA Study| Characteristics | BLINCYTO (N = 45) |
|---|
| Age | |
| Median, years (min, max) | 55 (23, 78) |
| ≥ 65 years and < 75 years, n (%) | 10 (22) |
| ≥ 75 years, n (%) | 2 (4) |
| Males, n (%) | 24 (53) |
| Race, n (%) | |
| Asian | 1 (2) |
| Black (or African American) | 3 (7) |
| Other | 2 (4) |
| White | 39 (87) |
| Disease History | |
| Prior TKI treatment Number of patients that failed ponatinib = 23 (51%) , n (%) | |
| 1 | 7 (16) |
| 2 | 21 (47) |
| ≥ 3 | 17 (38) |
| Prior salvage therapy | 31 (62) |
| Prior alloHSCT alloHSCT = allogeneic hematopoietic stem cell transplantation | 20 (44) |
| Bone marrow blasts centrally assessed | |
| ≥ 50% to < 75% | 6 (13) |
| ≥ 75% | 28 (62) |
Efficacy was based on the complete remission (CR) rate, duration of CR, and proportion of patients with an MRD-negative CR/CR with partial hematological recovery (CR/CRh*) within 2 cycles of treatment with BLINCYTO. Table 17 shows the efficacy results from ALCANTARA Study. Five of the 16 responding (31%) patients underwent allogeneic HSCT in CR/CRh* induced with BLINCYTO. There were 10 patients with documented T315I mutation; four achieved CR within 2 cycles of treatment with BLINCYTO.
Table 17. Efficacy Results in Patients ≥ 18 Years of Age with Philadelphia Chromosome-Positive Relapsed or Refractory B-cell Precursor ALL (ALCANTARA Study) | N = 45 |
|---|
| CR CR (complete remission) was defined as ≤ 5% of blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts (platelets > 100,000/microliter and absolute neutrophil counts [ANC] > 1,000/microliter). | CRh* CRh* (complete remission with partial hematological recovery) was defined as ≤ 5% of blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts (platelets > 50,000/microliter and ANC > 500/microliter). | CR/CRh* |
|---|
n (%) [95% CI] | 14 (31) [18, 47] | 2 (4) [1, 15] | 16 (36) [22, 51] |
| MRD response MRD (minimal residual disease) response was defined as MRD by PCR < 1 × 10-4 (0.01%). |
| n1/n2 (%) n1: number of patients who achieved MRD response and the respective remission status; n2: number of patients who achieved the respective remission status. Six CR/CRh* responders with missing MRD data were considered as MRD-nonresponders. [95% CI] | 12/14 (86) [57, 98] | 2/2 (100) [16, 100] | 14/16 (88) [62, 98] |
| DOR/RFS DOR (duration of response)/RFS (relapse-free survival) was defined as time since first response of CR or CRh* to relapse or death, whichever is earlier. Relapse was defined as hematological relapse (blasts in bone marrow greater than 5% following CR) or an extramedullary relapse. |
| Median (months) (range) | 6.7 (3.6 – 12.0) | NE NE = not estimable (3.7 – 9.0) | 6.7 (3.6 – 12.0) |
Study MT103-205
Study MT103-205 [NCT01471782] was an open-label, multicenter, single-arm study in pediatric patients with relapsed or refractory B-cell precursor ALL (second or later bone marrow relapse, any marrow relapse after allogeneic HSCT, or refractory to other treatments, and had > 25% blasts in bone marrow). BLINCYTO was administered at 5 mcg/m2/day on Days 1-7 and 15 mcg/m2/day on Days 8-28 for Cycle 1, and 15 mcg/m2/day on Days 1-28 for subsequent cycles. Dose adjustment was possible in case of adverse events. Patients who responded to BLINCYTO but later relapsed had the option to be retreated with BLINCYTO.
Among the 70 treated patients, the median age was 8 years (range: 7 months to 17 years), 40 out of 70 (57.1%) had undergone allogeneic HSCT prior to receiving BLINCYTO, and 39 out of 70 (55.7%) had refractory disease. The median number of treatment cycles was 1 (range: 1 to 5).
Twenty-three out of 70 (32.9%) patients achieved CR/CRh* within the first 2 treatment cycles with 17 out of 23 (73.9%) occurring within Cycle 1 of treatment. See Table 18 for the efficacy results from the study. The HSCT rate among those who achieved CR/CRh* was 48% (11 out of 23).
Table 18. Efficacy Results in Patients < 18 Years of Age with Relapsed or Refractory B-cell Precursor ALL (Study MT103-205) | N = 70 |
|---|
| CR CR (complete remission) was defined as ≤ 5% of blasts in the bone marrow, no evidence of circulating blasts or extra-medullary disease, and full recovery of peripheral blood counts (platelets > 100,000/microliter and absolute neutrophil counts [ANC] > 1,000/microliter). | CRh* CRh* (complete remission with partial hematological recovery) was defined as ≤ 5% of blasts in the bone marrow, no evidence of circulating blasts or extramedullary disease, and partial recovery of peripheral blood counts (platelets > 50,000/microliter and ANC > 500/microliter). | CR/CRh* |
|---|
n (%) [95% CI] | 12 (17.1) [9.2, 28.0] | 11 (15.7) [8.1, 26.4] | 23 (32.9) [22.1, 45.1] |
| MRD response MRD (minimal residual disease) response was defined as MRD by PCR or flow cytometry < 1 × 10-4 (0.01%). |
| n1/n2 (%) n1: number of patients who achieved MRD response and the respective remission status; n2: number of patients who achieved the respective remission status. One CR/CRh* responder with missing MRD data was considered as a MRD-nonresponder. [95% CI] | 6/12 (50.0) [21.1, 78.9] | 4/11 (36.4) [10.9, 69.2] | 10/23 (43.5) [23.2, 65.5] |
| DOR/RFS DOR (duration of response)/RFS (relapse-free survival) was defined as time since first response of CR or CRh* to relapse or death, whichever is earlier. Relapse was defined as hematological relapse (blasts in bone marrow greater than 5% following CR) or an extramedullary relapse. |
| Median (months) (range) | 6.0 (0.5 – 12.1) | 3.5 (0.5 – 16.4) | 6.0 (0.5 – 16.4) |
Study E1910
The efficacy of BLINCYTO was evaluated in a randomized, controlled study in adult patients with newly diagnosed Philadelphia chromosome-negative B-cell precursor ALL (Study E1910) [NCT02003222]. Eligible patients in hematologic complete remission (CR) or CR with incomplete peripheral blood count recovery (CRi) following induction and intensification chemotherapy were randomized 1:1 to receive a consolidation regimen comprised of multiple cycles of BLINCYTO monotherapy in addition to multiple cycles of intensive chemotherapy (BLINCYTO arm) or to intensive chemotherapy alone (chemotherapy arm). Randomization was stratified by age (< 55 years versus ≥ 55 years), CD20 status, rituximab use, and intent to undergo allogeneic stem cell transplantation (HSCT).
The postremission treatment consisted of a BFM-like chemotherapy regimen adapted from the E2993/UKALLXII clinical trial. Patients randomized to the BLINCYTO arm were to receive 2 cycles of BLINCYTO followed by 3 cycles of consolidation chemotherapy, then a third cycle of BLINCYTO followed by the fourth cycle of chemotherapy and a fourth cycle of BLINCYTO (total 8 cycles). BLINCYTO was administered as a continuous intravenous infusion at 28 mcg/day on Days 1-28. Patients randomized to the chemotherapy arm of the study were to receive 4 cycles of chemotherapy alone (total 4 cycles). Patients on the BLINCYTO arm could go to HSCT after 1 - 2 cycles of BLINCYTO and up to 2 cycles of consolidation chemotherapy, and patients randomized to the chemotherapy arm could go to HSCT after intensification and up to 3 cycles of consolidation chemotherapy. All patients who completed consolidation but did not go to HSCT received maintenance therapy through 2 1/2 years from the start of intensification.
The demographics and baseline characteristics are provided in Table 19.
Table 19. Demographics and Baseline Characteristics in Study E1910| Characteristics | Consolidation Consisting of |
|---|
BLINCYTO Cycles + Chemotherapy Cycles (n = 112) | Chemotherapy Cycles Alone (n = 112) |
|---|
| Age |
| Median, years (min, max) | 52 (31, 69) | 50 (30, 70) |
| Males, n (%) | 55 (49) | 56 (50) |
| Race, n (%) |
| American Indian or Alaska Native | 2 (2) | 1 (1) |
| Asian | 3 (3) | 2 (2) |
| Black (or African American) | 9 (8) | 4 (4) |
| Native Hawaiian or Other Pacific Islander | 1 (1) | 0 |
| White | 87 (78) | 89 (79) |
| Not Reported | 5 (4) | 6 (5) |
| Unknown | 5 (4) | 10 (9) |
| Ethnicity, n (%) | | |
| Hispanic or Latino | 13 (12) | 10 (9) |
| Not Hispanic or Latino | 95 (85) | 95 (85) |
| Not Reported | 1 (1) | 2 (2) |
| Unknown | 3 (3) | 5 (4) |
| Stratification Factors, n (%) |
| Age < 55 years at randomization | 65 (58) | 65 (58) |
| CD20 positive | 45 (40) | 46 (41) |
| Rituximab use | 33 (29) | 36 (32) |
| Planned allogeneic SCT allogeneic SCT = allogeneic stem cell transplantation. | 36 (32) | 35 (31) |
Efficacy was established on the basis of overall survival (OS). The results with a median follow-up of 3.6 years are shown in Figure 2 and Table 20.
Figure 2. Kaplan-Meier for Overall Survival in Study E1910KM = Kaplan-Meier. CI = Confidence Interval. N = Number of patients in the analysis set. Censor indicated by vertical bar. |
|
Table 20. Overall Survival in Study E1910 | BLINCYTO + Chemotherapy | Chemotherapy |
|---|
| CI = Confidence interval. Overall survival (OS) is calculated from time of randomization until death due to any cause. |
| Number of patients | 112 | 112 |
| Overall Survival |
| 3-year Kaplan-Meier estimate (%) [95% CI] | 84.8 [76.3, 90.4] | 69.0 [58.7, 77.2] |
| Hazard ratio [95% CI] The hazard ratio estimates are obtained from a stratified Cox regression model at the 3rd interim analysis. | 0.42 [0.24, 0.75] |
| p-value The p-value was derived using the stratified log rank test. | 0.003 |
In a later analysis with a median follow-up of 4.5 years, the 5-year OS was 82.4% [95% CI (73.7, 88.4)] in the BLINCYTO + chemotherapy arm and 62.5% [95% CI (52.0, 71.3)] in the chemotherapy arm. The hazard ratio was 0.44 [95% CI (0.25, 0.76)].
Study 20120215
The efficacy of BLINCYTO compared to consolidation chemotherapy was evaluated in a randomized, controlled, open-label, multicenter study (Study 20120215) [NCT02393859]. Eligible patients were 28 days to 18 years old and had high-risk, first-relapsed, Philadelphia chromosome-negative B-cell precursor ALL with < 25% blasts in the bone marrow after induction and 2 cycles of consolidation chemotherapy. Patients were randomized 1:1 to receive BLINCYTO or the IntReALLHR2010 HC3 intensive combination chemotherapy as the third cycle of consolidation. Patients in the BLINCYTO arm received one cycle of BLINCYTO as a continuous intravenous infusion at 15 mcg/m2/day over 4 weeks (maximum daily dose was not to exceed 28 mcg/day). Randomization was stratified by age, minimal residual disease status determined at the end of induction based on local assessment, and bone marrow status determined at the end of the second block of consolidation chemotherapy. Patients were to proceed to HSCT after this cycle of consolidation.
There were 54 patients randomized to the BLINCYTO arm and 57 to the chemotherapy arm. The demographics and baseline characteristics are shown in Table 21.
Table 21. Demographics and Baseline Characteristics in Study 20120215| Characteristics | Consolidation Cycle 3 |
|---|
BLINCYTO (N = 54) | Chemotherapy (N = 57) |
|---|
| N = number of patients in the analysis set; n = number of patients with observed data; MRD = minimal residual disease; PCR = polymerase chain reaction. |
| Age, n (%) |
| Median, (range) | 6 (1, 17) | 5 (1, 17) |
| < 1 year | 0 | 0 |
| 1 to 9 years | 39 (72) | 41 (72) |
| ≥ 10 to 18 years | 15 (28) | 16 (28) |
| Males, n (%) | 30 (56) | 23 (40) |
| Race, n (%) |
| American Indian or Alaska Native | 0 | 0 |
| Asian | 1 (2) | 3 (5) |
| Black (or African American) | 0 | 3 (5) |
| Native Hawaiian or Other Pacific Islander | 0 | 0 |
| Other | 3 (6) | 5 (9) |
| White | 50 (93) | 46 (81) |
| Cytomorphology at randomization, n (%) |
| Blasts < 5% | 54 (100) | 54 (95) |
| Blasts ≥ 5% and < 25% | 0 | 2 (4) |
| Blasts ≥ 25% blasts | 0 | 0 |
| Not evaluable | 0 | 1 (2) |
| MRD PCR value at randomization, n (%) |
| ≥ 10-3 | 11 (20) | 16 (28) |
| < 10-3 and ≥ 10-4 | 15 (28) | 6 (11) |
| < 10-4 | 20 (37) | 23 (40) |
| Unknown | 8 (15) | 12 (21) |
| Time from first diagnosis to relapse (month), n (%) |
| < 18 months | 19 (35) | 22 (39) |
| ≥ 18 months and ≤ 30 months | 32 (59) | 31 (54) |
| > 30 months | 3 (6) | 4 (7) |
Efficacy was established on the basis of overall survival (OS) and relapse-free survival (RFS). See Table 22, Figure 3, and Figure 4 for results of OS and RFS from Study 20120215.
Table 22. Efficacy Results in Pediatric Patients with High-Risk First Relapsed B-cell Precursor ALL (Study 20120215) | Consolidation Cycle 3 |
|---|
| BLINCYTO (N = 54) | Chemotherapy (N = 57) |
|---|
| NE = Not estimable. CI = Confidence interval. |
| Overall Survival |
| Number of deaths (%) | 11 (20.4) | 28 (49.1) |
| 5-year KM estimate (%) [95% CI] Months were calculated as days from randomization date to event/censor date, divided by 30.5. | 78.4 [64.2, 87.4] | 41.4 [26.3, 55.9] |
| Hazard Ratio [95% CI] The hazard ratio estimates are obtained from the Cox proportional hazard model. | 0.35 [0.17, 0.70] |
| Relapse-free Survival |
| Events, n (%) | 20 (37.0) | 37 (64.9) |
| 5-year KM estimate (%) [95% CI] | 61.1 [46.3, 72.9] | 27.6 [16.2, 40.3] |
| Hazard Ratio [95% CI] | 0.38 [0.22, 0.66] |
The median follow-up time for OS was 55.2 months for the overall population. Figure 3 presents a Kaplan-Meier plot comparing OS between treatment arms for the overall population.
Figure 3. Kaplan-Meier for Overall Survival (Study 20120215)KM = Kaplan-Meier. CI = Confidence Interval. N = Number of patients in the analysis set. Censor indicated by vertical bar. |
|
Figure 4. Kaplan-Meier for Relapse-free Survival (Study 20120215)KM = Kaplan-Meier. CI = Confidence Interval. N = Number of patients in the analysis set. Censor indicated by vertical bar. |
|
Cytokine Release Syndrome (CRS)
Advise patients of the risk of CRS and infusion reactions, and to contact their healthcare professional for signs and symptoms associated with CRS or infusion reactions (pyrexia, fatigue, nausea, vomiting, chills, hypotension, rash, and wheezing) [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)].
Neurological Toxicities, including Immune Effector Cell-Associated Neurotoxicity Syndrome
Advise patients of the risk of neurological toxicities, including ICANS, and to contact their healthcare professional for signs and symptoms associated with this event (including convulsions, speech disorders, and confusion) [see Warnings and Precautions (5.2) and Adverse Reactions (6.1)].
Infections
Advise patients of the risk of infections, and to contact their healthcare professional for signs or symptoms of infection [see Warnings and Precautions (5.3) and Adverse Reactions (6.1)].
Inform patients of the importance of keeping the skin clean around the intravenous catheter to reduce the risk of infection.
Pancreatitis
Advise patients of the risk of pancreatitis and to contact their healthcare provider for signs or symptoms of pancreatitis, which include severe and persistent stomach pain, with or without nausea and vomiting [see Warnings and Precautions (5.8) and Adverse Reactions (6.2)].
Driving and Engaging in Hazardous Occupations
Advise patients to refrain from driving and engaging in hazardous occupations or activities such as operating heavy or potentially dangerous machinery while BLINCYTO is being administered. Patients should be advised that they may experience neurological events, including seizures and ICANS [see Warnings and Precautions (5.6)].
Infusion Pump Errors
Inform patients they should not adjust the setting on the infusion pump. Any changes to pump function may result in dosing errors. If there is a problem with the infusion pump or the pump alarms, patients should contact their doctor or nurse immediately.
Embryo-Fetal Toxicity
Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider if they are pregnant or become pregnant [see Warnings and Precautions (5.13) and Use in Specific Populations (8.1)]. Advise females of reproductive potential to use effective contraception during treatment with BLINCYTO and for 48 hours after the last dose [see Warnings and Precautions (5.13) and Use in Specific Populations (8.3)].
Lactation
Advise women not to breastfeed during treatment with BLINCYTO and for 48 hours after the last dose [see Use in Specific Populations (8.2)].
BLINCYTO® (blinatumomab)
Manufactured by:
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, California 91320-1799
U.S. License No. 1080
Patent: http://pat.amgen.com/blincyto/
© 2014-2026 Amgen Inc. All rights reserved.
V21
| 24-Hour or 48-Hour Infusion |
INSTRUCTIONS FOR USE: 24-HOUR OR 48-HOUR INFUSION The preparation steps differ based on the infusion duration. Follow the steps specific to the infusion duration you are preparing. It is very important that the instructions for preparation (including admixing) and administration provided in this section are strictly followed to minimize medication errors (including underdose and overdose) [see Dosage and Administration (2.5), Warnings and Precautions (5.10)]. |
| |
Aseptic Preparation Strictly observe aseptic technique when preparing the solution for infusion since BLINCYTO vials do not contain antimicrobial preservatives. To prevent accidental contamination, prepare BLINCYTO according to aseptic standards, including but not limited to: - Prepare BLINCYTO in a USP <797> compliant facility.
- Prepare BLINCYTO in an ISO Class 5 laminar flow hood or better.
- Ensure that the admixing area has appropriate environmental specifications, confirmed by periodic monitoring.
- Ensure that personnel are appropriately trained in aseptic manipulations and admixing of oncology drugs.
- Ensure that personnel wear appropriate protective clothing and gloves.
- Ensure that gloves and surfaces are disinfected.
Gather Equipment and Supplies for 24-Hour or 48-Hour Infusion- Preservative-Free Sterile Water for Injection, USP.
- Preservative-Free 0.9% Sodium Chloride Injection, USP.
- Sterile, non-pyrogenic, low protein-binding, 0.2 micron in-line filter.
- Infusion bags/pump cassettes and intravenous tubing sets: Use either polyolefin, DEHP-free PVC, or ethyl vinyl acetate (EVA).
- -BLINCYTO is incompatible with diethylhexylphthalate (DEHP) due to the possibility of particle formation, leading to a cloudy solution.
- BLINCYTO package(s), each BLINCYTO package contains:
- One BLINCYTO for injection 35 mcg single-dose vial containing a sterile, preservative-free, white to off-white lyophilized powder. -
- -More than one vial of BLINCYTO may be needed to prepare the recommended dose.
- -One IV Solution Stabilizer 10 mL single-dose glass vial containing a sterile, preservative-free, colorless to slightly yellow, clear solution.
- -Do not use IV Solution Stabilizer for reconstitution of BLINCYTO.
- -IV Solution Stabilizer is used to coat the intravenous bag prior to addition of reconstituted BLINCYTO to prevent adhesion of BLINCYTO to intravenous bags and intravenous tubing.
|
| |
Preparation of BLINCYTO: Reconstitution- 1.Determine the number of BLINCYTO vials needed for a dose and infusion duration.
- Refer to Table 1 (patients weighing 45 kg or more) or Table 2 (patients weighing less than 45 kg).
- a.Reconstitute each BLINCYTO vial with 3 mL of preservative-free Sterile Water for Injection, USP by directing the water along the walls of the BLINCYTO vial and not directly on the lyophilized powder. The resulting concentration per BLINCYTO vial is 12.5 mcg/mL.
- Do not reconstitute BLINCYTO vials with the IV Solution Stabilizer (IVSS).
|
| | | | |
| 3 mL of Preservative-Free Sterile Water for Injection, USP | | Lyophilized BLINCYTO | | Reconstituted BLINCYTO |
| Important: Do not reconstitute BLINCYTO vials with IV Solution Stabilizer (IVSS). |
- b.Gently swirl contents to avoid excess foaming.
- c.Visually inspect the reconstituted solution for particulate matter and discoloration during reconstitution and prior to preparing the intravenous bag. The resulting solution should be clear to slightly opalescent, colorless to slightly yellow.
- Do not use if solution is cloudy or has precipitated.
Preparation of BLINCYTO: 24-Hour or 48-Hour Intravenous Bag- 2.Aseptically add 270 mL of preservative-free 0.9% Sodium Chloride Injection, USP to the empty intravenous bag.
|
| 270 mL of Preservative-Free 0.9% NaCl Injection, USP | | | Empty IV Bag Material, use either:- Polyolefin,
- DEHP-free PVC, or
- EVA IV Bag
|
- 3.Aseptically transfer 5.5 mL of IV Solution Stabilizer (IVSS) to the intravenous bag containing preservative-free 0.9% Sodium Chloride Injection, USP.
- Gently mix the contents of the bag to avoid foaming.
|
| IV Solution Stabilizer | - For 24-hour infusion, transfer 5.5 mL IV Solution Stabilizer.
- For 48-hour infusion, transfer 5.5 mL IV Solution Stabilizer.
- Discard the vial containing the unused IV Solution Stabilizer.
|
- 4.Aseptically transfer the required volume of reconstituted BLINCYTO solution into the intravenous bag containing preservative-free 0.9% Sodium Chloride Injection, USP and IV Solution Stabilizer.
- Gently mix the contents of the bag to avoid foaming.
|
| Reconstituted BLINCYTO | - Refer to Table 1 for patients weighing 45 kg or more for the specific volume of reconstituted BLINCYTO.
- Refer to Table 2 for patients weighing less than 45 kg (dose based on BSA) for the specific volume of reconstituted BLINCYTO.
- Discard the vial containing unused BLINCYTO.
|
- 5.Remove air from the intravenous bag. This is particularly important for use with an ambulatory infusion pump.
- 6.Under aseptic conditions, attach the intravenous tubing to the intravenous bag with the sterile 0.2 micron in-line filter.
- Ensure that the intravenous tubing is compatible with the infusion pump.
- Use either polyolefin, DEHP-free PVC or EVA intravenous tubing sets.
- 7.Prime the intravenous tubing only with the solution in the bag containing the FINAL prepared BLINCYTO solution for infusion.
- 8.Store refrigerated at 2°C to 8°C (36°F to 46°F) if not used immediately [see Dosage and Administration (2.6)].
|
| |
| |
| Table 1. For 24-Hour and 48-Hour Infusion: Patients Weighing 45 kg or More | |
| Infusion Duration | Dose | Reconstituted BLINCYTO | |
| Volume | Vials | |
| 24 hours | 9 mcg/day | 0.83 mL | 1 | |
| 28 mcg/day | 2.6 mL | 1 | |
| 48 hours | 9 mcg/day | 1.7 mL | 1 | |
| 28 mcg/day | 5.2 mL | 2 | |
| | | | | | | | | | |
| Table 2. For 24-Hour and 48-Hour Infusion: Patients Weighing Less Than 45 kg | |
| Infusion Duration | Dose | BSA (m2) | Reconstituted BLINCYTO | |
| Volume | Vials | |
| 24 hours | 5 mcg/m2/day | 1.5 – 1.59 | 0.7 mL | 1 | |
| 1.4 – 1.49 | 0.66 mL | 1 | |
| 1.3 – 1.39 | 0.61 mL | 1 | |
| 1.2 – 1.29 | 0.56 mL | 1 | |
| 1.1 – 1.19 | 0.52 mL | 1 | |
| 1 – 1.09 | 0.47 mL | 1 | |
| 0.9 – 0.99 | 0.43 mL | 1 | |
| 0.8 – 0.89 | 0.38 mL | 1 | |
| 0.7 – 0.79 | 0.33 mL | 1 | |
| 0.6 – 0.69 | 0.29 mL | 1 | |
| 0.5 – 0.59 | 0.24 mL | 1 | |
| 0.4 – 0.49 | 0.2 mL | 1 | |
| 0.35 – 0.39 | 0.17 mL | 1 | |
| 0.3 – 0.34 | 0.15 mL | 1 | |
| 0.25 – 0.29 | 0.12 mL | 1 | |
| 0.2 – 0.24 | 0.1 mL | 1 | |
| 24 hours | 15 mcg/m2/day | 1.5 – 1.59 | 2.1 mL | 1 | |
| 1.4 – 1.49 | 2 mL | 1 | |
| 1.3 – 1.39 | 1.8 mL | 1 | |
| 1.2 – 1.29 | 1.7 mL | 1 | |
| 1.1 – 1.19 | 1.6 mL | 1 | |
| 1 – 1.09 | 1.4 mL | 1 | |
| 0.9 – 0.99 | 1.3 mL | 1 | |
| 0.8 – 0.89 | 1.1 mL | 1 | |
| 0.7 – 0.79 | 1 mL | 1 | |
| 0.6 – 0.69 | 0.86 mL | 1 | |
| 0.5 – 0.59 | 0.72 mL | 1 | |
| 0.4 – 0.49 | 0.59 mL | 1 | |
| 0.35 – 0.39 | 0.51 mL | 1 | |
| 0.3 – 0.34 | 0.44 mL | 1 | |
| 0.25 – 0.29 | 0.37 mL | 1 | |
| 0.2 – 0.24 | 0.3 mL | 1 | |
| 48 hours | 5 mcg/m2/day | 1.5 – 1.59 | 1.4 mL | 1 | |
| 1.4 – 1.49 | 1.3 mL | 1 | |
| 1.3 – 1.39 | 1.2 mL | 1 | |
| 1.2 – 1.29 | 1.1 mL | 1 | |
| 1.1 – 1.19 | 1 mL | 1 | |
| 1 – 1.09 | 0.94 mL | 1 | |
| 0.9 – 0.99 | 0.85 mL | 1 | |
| 0.8 – 0.89 | 0.76 mL | 1 | |
| 0.7 – 0.79 | 0.67 mL | 1 | |
| 0.6 – 0.69 | 0.57 mL | 1 | |
| 0.5 – 0.59 | 0.48 mL | 1 | |
| 0.4 – 0.49 | 0.39 mL | 1 | |
| 0.35 – 0.39 | 0.34 mL | 1 | |
| 0.3 – 0.34 | 0.29 mL | 1 | |
| 0.25 – 0.29 | 0.25 mL | 1 | |
| 0.2 – 0.24 | 0.2 mL | 1 | |
| 48 hours | 15 mcg/m2/day | 1.5 – 1.59 | 4.2 mL | 2 | |
| 1.4 – 1.49 | 3.9 mL | 2 | |
| 1.3 – 1.39 | 3.7 mL | 2 | |
| 1.2 – 1.29 | 3.4 mL | 2 | |
| 1.1 – 1.19 | 3.1 mL | 2 | |
| 1 – 1.09 | 2.8 mL | 1 | |
| 0.9 – 0.99 | 2.6 mL | 1 | |
| 0.8 – 0.89 | 2.3 mL | 1 | |
| 0.7 – 0.79 | 2 mL | 1 | |
| 0.6 – 0.69 | 1.7 mL | 1 | |
| 0.5 – 0.59 | 1.4 mL | 1 | |
| 0.4 – 0.49 | 1.2 mL | 1 | |
| 0.35 – 0.39 | 1 mL | 1 | |
| 0.3 – 0.34 | 0.88 mL | 1 | |
| 0.25 – 0.29 | 0.75 mL | 1 | |
| 0.2 – 0.24 | 0.61 mL | 1 | |
| |
Administration of BLINCYTO: 24-Hour or 48-Hour Intravenous Bag- Administer BLINCYTO as a continuous intravenous infusion at a constant flow rate using an infusion pump. The pump should be programmable, lockable, non-elastomeric, and have an alarm.
- The starting volume (270 mL) is more than the volume administered to the patient (240 mL) to account for the priming of the intravenous tubing and to ensure that the patient will receive the full dose of BLINCYTO.
- Ensure that the intravenous tubing is primed only with the solution in the bag containing the FINAL prepared BLINCYTO solution for infusion.
- Administer the FINAL prepared BLINCYTO infusion solution using intravenous tubing that contains a sterile, non-pyrogenic, low protein-binding, 0.2 micron in-line filter for 24-hour or 48-hour bags.
- Infuse the FINAL prepared BLINCYTO infusion solution according to the instructions on the pharmacy label on the prepared bag at one of the following constant infusion rates:
- -Infusion rate of 10 mL/hour for a duration of 24 hours, OR
- -Infusion rate of 5 mL/hour for a duration of 48 hours.
- Important Note: Do not flush the BLINCYTO infusion line, especially when changing infusion bags. Flushing when changing bags or at completion of infusion can result in excess dosage and complications thereof. When administering via a multi-lumen venous catheter, infuse BLINCYTO through a dedicated lumen. Before flushing the catheter system, residual amounts of BLINCYTO must be aspirated from the catheter system to avoid bolus administration.
- At the end of the infusion, any remaining solution in the intravenous bag and intravenous tubing should be discarded in accordance with local requirements.
|
| 72-Hour, 96-Hour, or 7-Day Infusion (Preservative) |
INSTRUCTIONS FOR USE: 72-HOUR OR 96-HOUR, OR 7-DAY INFUSION The preparation steps differ based on the infusion duration. Follow the steps specific to the infusion duration you are preparing. It is very important that the instructions for preparation (including admixing) and administration provided in this section are strictly followed to minimize medication errors (including underdose and overdose) [see Dosage and Administration (2.5), Warnings and Precautions (5.10)]. The administration of BLINCYTO as a 72-hour, 96-hour, and 7-day infusion is not recommended for patients weighing less than 5.4 kg [see Warnings and Precautions (5.12)]. |
| |
Aseptic Preparation Strictly observe aseptic technique when preparing the solution for infusion since BLINCYTO vials do not contain antimicrobial preservatives. To prevent accidental contamination, prepare BLINCYTO according to aseptic standards, including but not limited to: - Prepare BLINCYTO in a USP <797> compliant facility.
- Prepare BLINCYTO in an ISO Class 5 laminar flow hood or better.
- Ensure that the admixing area has appropriate environmental specifications, confirmed by periodic monitoring.
- Ensure that personnel are appropriately trained in aseptic manipulations and admixing of oncology drugs.
- Ensure that personnel wear appropriate protective clothing and gloves.
- Ensure that gloves and surfaces are disinfected.
Gather Equipment and Supplies for 72-Hour, 96-Hour, or 7-Day Infusion- Preservative-Free Sterile Water for Injection, USP.
- Preservative-Free 0.9% Sodium Chloride Injection, USP.
- Bacteriostatic 0.9% Sodium Chloride Injection, USP.
- Infusion bags/pump cassettes and intravenous tubing sets: Use either polyolefin, DEHP-free PVC, or ethyl vinyl acetate (EVA).
- -BLINCYTO is incompatible with diethylhexylphthalate (DEHP) due to the possibility of particle formation, leading to a cloudy solution.
- BLINCYTO package(s), each BLINCYTO package contains:
- One BLINCYTO for injection 35 mcg single-dose vial containing a sterile, preservative-free, white to off-white lyophilized powder. -
- -More than one vial of BLINCYTO may be needed to prepare the recommended dose.
- -One IV Solution Stabilizer 10 mL single-dose glass vial containing a sterile, preservative-free, colorless to slightly yellow, clear solution.
- -Do not use IV Solution Stabilizer for reconstitution of BLINCYTO.
- -IV Solution Stabilizer is used to coat the intravenous bag prior to addition of reconstituted BLINCYTO to prevent adhesion of BLINCYTO to intravenous bags and intravenous tubing.
|
| | | | | | | | | | | |
Preparation of BLINCYTO: Reconstitution- 1.Determine the number of BLINCYTO vials needed for a dose and infusion duration.
- Refer to Table 3 (patients weighing 45 kg or more) or Table 4 (patients weighing between 5.4 kg and less than 45 kg).
- a.Reconstitute each BLINCYTO vial with 3 mL of preservative-free Sterile Water for Injection, USP by directing the water along the walls of the BLINCYTO vial and not directly on the lyophilized powder. The resulting concentration per BLINCYTO vial is 12.5 mcg/mL.
- Do not reconstitute BLINCYTO vials with the IV Solution Stabilizer (IVSS).
|
| | | | |
| 3 mL of Preservative-Free Sterile Water for Injection, USP | | Lyophilized BLINCYTO | | Reconstituted BLINCYTO |
| Important: Do not reconstitute BLINCYTO vials with IV Solution Stabilizer (IVSS). |
- b.Gently swirl contents to avoid excess foaming.
- c.Visually inspect the reconstituted solution for particulate matter and discoloration during reconstitution and prior to preparing the intravenous bag. The resulting solution should be clear to slightly opalescent, colorless to slightly yellow.
- Do not use if solution is cloudy or has precipitated.
Preparation of BLINCYTO: 72-Hour, 96-Hour, or 7-Day Intravenous Bag- 2.Aseptically add the required volume of Bacteriostatic 0.9% Sodium Chloride Injection, USP to the empty intravenous bag.
- For 72-hour infusion, add 45 mL Bacteriostatic 0.9% Sodium Chloride Injection.
- For 96-hour infusion, add 56 mL Bacteriostatic 0.9% Sodium Chloride Injection.
- For 7-day infusion, add 90 mL Bacteriostatic 0.9% Sodium Chloride Injection.
|
| Bacteriostatic 0.9% NaCl Injection, USP | | | Empty IV Bag Material, use either:- Polyolefin,
- DEHP-free PVC, or
- EVA IV Bag
|
- 3.Aseptically transfer the required volume of IV Solution Stabilizer (IVSS) to the intravenous bag containing Bacteriostatic 0.9% Sodium Chloride Injection, USP.
- Gently mix the contents of the bag to avoid foaming.
|
| IV Solution Stabilizer | - For 72-hour infusion, transfer 3.2 mL IV Solution Stabilizer.
- For 96-hour infusion, transfer 4 mL IV Solution Stabilizer.
- For 7-day infusion, transfer 2.2 mL IV Solution Stabilizer.
- Discard the vial containing the unused IV Solution Stabilizer.
|
- 4.Aseptically transfer the required volume of reconstituted BLINCYTO solution into the intravenous bag containing Bacteriostatic 0.9% Sodium Chloride Injection, USP and IV Solution Stabilizer.
- Gently mix the contents of the bag to avoid foaming.
|
| Reconstituted BLINCYTO | - Refer to Table 3 for patients weighing 45 kg or more for the specific volume of reconstituted BLINCYTO.
- Refer to Table 4 for patients weighing between 5.4 kg and less than 45 kg (dose based on BSA) for the specific volume of reconstituted BLINCYTO.
- Discard the vial containing unused BLINCYTO.
|
- 5.Aseptically add the needed volume of preservative-free 0.9% Sodium Chloride Injection, USP to the intravenous bag to obtain the final volumes within Table 3 and Table 4.
- Gently mix the contents of the bag to avoid foaming.
|
| Preservative-Free 0.9% NaCl Injection, USP | - Refer to Table 3 for patients weighing 45 kg or more for the specific volume of preservative-free 0.9% Sodium Chloride Injection, USP.
- Refer to Table 4 for patients weighing between 5.4 kg and less than 45 kg (dose based on BSA) for the specific volume of preservative-free 0.9% Sodium Chloride Injection, USP.
|
- 6.Remove air from the intravenous bag. This is particularly important for use with an ambulatory infusion pump.
- 7.Under aseptic conditions, attach the intravenous tubing to the intravenous bag. Do not use an in-line filter for 72-hour, 96-hour, or 7-day bags.
- Ensure that the intravenous tubing is compatible with the infusion pump.
- Use either polyolefin, DEHP-free PVC or EVA intravenous tubing sets.
|
| Important: Do not use an in-line filter for 72-hour, 96-hour, or 7-day bags. |
- 8.Prime the intravenous tubing only with the solution in the bag containing the FINAL prepared BLINCYTO solution for infusion.
- 9.Store refrigerated at 2°C to 8°C (36°F to 46°F) if not used immediately [see Dosage and Administration (2.6)].
|
| |
| |
| Table 3. For 72-Hour, 96-Hour, and 7-Day Infusion: Patients Weighing 45 kg or More | |
| Infusion Duration | Dose | Reconstituted BLINCYTO | Volume of Preservative-Free 0.9% Sodium Chloride Injection, USP needed to q.s. to Final Volume | Final Volume of IV Bag | |
| Volume | Vials | |
| 72 hours | 28 mcg/day | 8.4 mL | 3 | 105 mL | 162 mL | |
| 96 hours | 28 mcg/day | 10.4 mL | 4 | 130 mL | 200 mL | |
| 7 days | 28 mcg/day | 16.8 mL | 6 | 1 mL | 110 mL | |
| |
| Table 4. For 72-Hour, 96-Hour, and 7-Day Infusion: Patients Weighing Between 5.4 kg and Less Than 45 kg | |
| Infusion Duration | Dose | BSA (m2) | Reconstituted BLINCYTO | Volume of Preservative-Free 0.9% Sodium Chloride Injection, USP needed to q.s. to Final Volume | Final Volume of IV Bag | |
| Volume | Vials | |
| 72 hours | 15 mcg/m2/day | 1.5 – 1.59 | 6.8 mL | 3 | 107 mL | 162 mL | |
| 1.4 – 1.49 | 6.4 mL | 3 | 107 mL | 162 mL | |
| 1.30 – 1.39 | 6 mL | 3 | 108 mL | 162 mL | |
| 1.20 – 1.29 | 5.4 mL | 2 | 108 mL | 162 mL | |
| 1.10 – 1.19 | 5 mL | 2 | 109 mL | 162 mL | |
| 1 – 1.09 | 4.6 mL | 2 | 109 mL | 162 mL | |
| 0.9 – 0.99 | 4.2 mL | 2 | 110 mL | 162 mL | |
| 0.8 – 0.89 | 3.8 mL | 2 | 110 mL | 162 mL | |
| 0.7 – 0.79 | 3.2 mL | 2 | 111 mL | 162 mL | |
| 0.6 – 0.69 | 2.8 mL | 1 | 111 mL | 162 mL | |
| 0.5 – 0.59 | 2.3 mL | 1 | 111 mL | 162 mL | |
| 0.4 – 0.49 | 2 mL | 1 | 112 mL | 162 mL | |
| 0.35 – 0.39 | 1.7 mL | 1 | 112 mL | 162 mL | |
| 0.3 – 0.34 | 1.4 mL | 1 | 112 mL | 162 mL | |
| 0.25 – 0.29 | 1.2 mL | 1 | 113 mL | 162 mL | |
| 96 hours | 15 mcg/m2/day | 1.5 – 1.59 | 8.4 mL | 3 | 132 mL | 200 mL | |
| 1.4 – 1.49 | 7.8 mL | 3 | 132 mL | 200 mL | |
| 1.30 – 1.39 | 7.4 mL | 3 | 133 mL | 200 mL | |
| 1.20 – 1.29 | 6.8 mL | 3 | 133 mL | 200 mL | |
| 1.10 – 1.19 | 6.2 mL | 3 | 134 mL | 200 mL | |
| 1 – 1.09 | 5.6 mL | 2 | 134 mL | 200 mL | |
| 0.9 – 0.99 | 5.2 mL | 2 | 135 mL | 200 mL | |
| 0.8 – 0.89 | 4.6 mL | 2 | 135 mL | 200 mL | |
| 0.7 – 0.79 | 4 mL | 2 | 136 mL | 200 mL | |
| 0.6 – 0.69 | 3.4 mL | 2 | 137 mL | 200 mL | |
| 0.5 – 0.59 | 2.8 mL | 1 | 137 mL | 200 mL | |
| 0.4 – 0.49 | 2.4 mL | 1 | 138 mL | 200 mL | |
| 0.35 – 0.39 | 2.1 mL | 1 | 138 mL | 200 mL | |
| 0.3 – 0.34 | 1.8 mL | 1 | 138 mL | 200 mL | |
| 0.25 – 0.29 | 1.5 mL | 1 | 139 mL | 200 mL | |
| 7 days | 15 mcg/m2/day | 1.5 – 1.59 | 14 mL | 5 | 3.8 mL | 110 mL | |
| 1.4 – 1.49 | 13.1 mL | 5 | 4.7 mL | 110 mL | |
| 1.30 – 1.39 | 12.2 mL | 5 | 5.6 mL | 110 mL | |
| 1.20 – 1.29 | 11.3 mL | 5 | 6.5 mL | 110 mL | |
| 1.10 – 1.19 | 10.4 mL | 4 | 7.4 mL | 110 mL | |
| 1 – 1.09 | 9.5 mL | 4 | 8.3 mL | 110 mL | |
| 0.9 – 0.99 | 8.6 mL | 4 | 9.2 mL | 110 mL | |
| 0.8 – 0.89 | 7.7 mL | 3 | 10.1 mL | 110 mL | |
| 0.7 – 0.79 | 6.8 mL | 3 | 11 mL | 110 mL | |
| 0.6 – 0.69 | 5.9 mL | 3 | 11.9 mL | 110 mL | |
| 0.5 – 0.59 | 5 mL | 2 | 12.8 mL | 110 mL | |
| 0.4 – 0.49 | 4.1 mL | 2 | 13.7 mL | 110 mL | |
| 0.35 – 0.39 | 3.4 mL | 2 | 14.4 mL | 110 mL | |
| 0.3 – 0.34 | 2.8 mL | 1 | 15 mL | 110 mL | |
| 0.25 – 0.29 | 2.5 mL | 1 | 15.3 mL | 110 mL | |
| The administration of BLINCYTO as a 72-hour, 96-hour, and 7-day infusion is not recommended for patients weighing less than 5.4 kg. |
Administration of BLINCYTO: 72-Hour, 96-Hour, or 7-Day Intravenous Bag- Administer BLINCYTO as a continuous intravenous infusion at a constant flow rate using an infusion pump. The pump should be programmable, lockable, non-elastomeric, and have an alarm.
- The final volume of infusion solution will be more than the volume administered to the patient to account for the priming of the intravenous tubing and to ensure that the patient will receive the full dose of BLINCYTO.
- -For 72-hour infusion (162 mL) will be more than the volume administered to the patient (130 mL).
- -For 96-hour infusion (200 mL) will be more than the volume administered to the patient (173 mL).
- -For 7-day infusion (110 mL) will be more than the volume administered to the patient (100 mL).
- Ensure that the intravenous tubing is primed only with the solution in the bag containing the FINAL prepared BLINCYTO solution for infusion.
- Do not use an in-line filter for 72-hour, 96-hour, or 7-day bags.
- Infuse the FINAL prepared BLINCYTO infusion solution according to the instructions on the pharmacy label on the prepared bag at one of the following constant infusion rates:
- -Infusion rate of 1.8 mL/hour for a duration of 72 hours or 96 hours, OR
- -Infusion rate of 0.6 mL/hour for a duration of 7 days.
- Important Note: Do not flush the BLINCYTO infusion line, especially when changing infusion bags. Flushing when changing bags or at completion of infusion can result in excess dosage and complications thereof. When administering via a multi-lumen venous catheter, infuse BLINCYTO through a dedicated lumen. Before flushing the catheter system, residual amounts of BLINCYTO must be aspirated from the catheter system to avoid bolus administration.
- At the end of the infusion, any remaining solution in the intravenous bag and intravenous tubing should be discarded in accordance with local requirements.
|
Manufactured by:
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, California 91320-1799
U.S. License No. 1080
BLINCYTO® (blinatumomab)
Patent: http://pat.amgen.com/blincyto/
© 2024 Amgen Inc. All rights reserved.
V2
Revised: 12/2024